FcγRIIIa, FcγRIIIa+ NK cells, and macrophages are retained in treatment-resistant TNBC and are spatially associated with FRα+ tumor areas at baseline and following neoadjuvant therapy. The gene discussed is FOLR1; the disease is neoplasm.